MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST000055/mwtabprimaryOK200MetabolomicsMass SpectrometryESIMus Musculushttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST000055Treatment:GSK inhibitor | Collection Time (h):48Treatment:GSK inhibitor | Collection Time (h):24Treatment:AZD inhibitor | Collection Time (h):0Treatment:Media alone | Collection Time (h):4Treatment:AZD inhibitor | Collection Time (h):4Treatment:AZD inhibitor | Collection Time (h):48Treatment:Media alone | Collection Time (h):48Treatment:Media alone | Collection Time (h):0Treatment:AZD inhibitor | Collection Time (h):24Treatment:GSK inhibitor | Collection Time (h):0Treatment:Media alone | Collection Time (h):24Treatment:GSK inhibitor | Collection Time (h):4Aml CellsUniversity of North CarolinaMS positive ion mode.MetabolomicsWorkbenchSTK1, Transphosphorylases, FLT3, B230315G04, FLT-3, Metabolic, tyrosine-protein kinase receptor flk-2, Kinases, Metabolomes, Profile, tyrosine-protein kinase receptor FLT3, FLK-2, tyrosine-protein kinase FLT3, STK-1, Profiles, Transphosphorylase, Fms-like tyrosine kinase 3, Phosphotransferases, CD135, acute myelogenous leukemia cell, Metabolic Profiles., Flk-2, wmfl, acute myeloblastic leukemia cell, Ly72, Flk2, FLK2, AML cell, fetal liver kinase 2, Kinase, ATP Phosphotransferases, Flt-3, Metabolic Profile, Phosphotransferase, FL cytokine receptor, ATP, stem cell tyrosine kinase 1iones., Ionen, ion, Ion, ionsfalseEffect of kinase inhibitors on FLT3-ITD AML cell metabolomesST00005510090